GlassScriptPhysician profile
Daniel R Kim
NPI 1568099646
$1,016.48
in general payments reported to CMS, 2019-2025
12 companies · $752 in 2025
The $752 reported for 2025 was more than what 88% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
See the full distribution for Sports Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.29 · 2024: $248 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $182.08 | 2025 | Evenity, Otezla, Repatha |
| Bioventus LLC | $172.62 | 2024-2025 | Xcell, Supartz Fx Sodium Hyaluronate, Durolane |
| Exact Sciences Corporation | $160.75 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $120.88 | 2024 | |
| Aimmune Therapeutics, INC. | $120.15 | 2025 | Zenpep |
| Pfizer INC. | $82.80 | 2023-2025 | |
| Averitas Pharma INC. | $66.12 | 2025 | Qutenza |
| Echosens North America, INC. | $29.42 | 2025 | Fibroscan |
| Vertex Pharmaceuticals Incorporated | $27.00 | 2025 | |
| Depuy Synthes Sales INC. | $20.12 | 2025 | Orthovisc, Monovisc |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.08 | 2025 | Caplyta |
| Avanos Medical | $15.46 | 2024 | Trivisc Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.